Two Phase 1 drugs (CX-4945, JQ1) can work together to efficiently kill T-cell acute lymphoblastic leukemia cells while having minimal impact on normal blood cells.
Acute Lymphoblastic Leukemia - Incidence Causes Symptoms Diagnosis Treatment Prognosis
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lymphoblasts. It is the most common of all childhood cancers and can be fatal in weeks if left untreated.
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lymphoblasts. It is the most common of all childhood cancers and can be fatal in weeks if left untreated.
‘Two Phase 1 drugs (CX-4945 and JQ1) can work together to efficiently kill T-cell acute lymphoblastic leukemia cells while having minimal impact on normal blood cells.’
Researchers have determined that these two Phase 1 drugs (CX-4945 and JQ1)
can work together to efficiently kill T-cell acute lymphoblastic
leukemia cells while having minimal impact on normal blood cells.
Although both drugs were previously tested as single agents in
clinical trials to treat cancers, the success of the combined actions on
cancer cells was previously unknown until now. The findings appear in
the journal Haematologica. "Previous studies provided us a rationale to test the combination of CX-4945 and JQ1 on refractory/relapsed T-cell leukemia," said corresponding author Hui Feng, assistant professor of pharmacology & experimental therapeutics at Boston University School of Medicine (BUSM). "Our findings suggest that the combination treatment of CX-4945 and JQ1 could be an effective strategy to target refractory/relapsed T-cell leukemia," she added.
According to the researchers the efficacy of using a combination of JQ1 and CX-4945 in treating other cancers should also be investigated.
Gene Therapy Could be the Silver Lining for Patients Suffering from Acute Lymphoblastic Leukemia
A recent research on cancer treatment using gene therapy has produced promising results in treating lethal leukemia.
A recent research on cancer treatment using gene therapy has produced promising results in treating lethal leukemia.
Therapies for Children Benefits Young Adults With Acute Lymphoblastic Leukemia
Adolescent and young adult patients, aged 16 to 19, with acute lymphoblastic leukemia tend to fare better when treated with high-intensity pediatric protocols.
Adolescent and young adult patients, aged 16 to 19, with acute lymphoblastic leukemia tend to fare better when treated with high-intensity pediatric protocols.
Identification Of Biomarkers of Behavior, Therapeutic Targets for Adult B-acute Lymphoblastic Leukemia By Researchers
Researchers provided with a potential new prognostic biomarker thanks to new insight into the aggressive behavior of certain adult B-acute lymphoblastic leukemias.
Researchers provided with a potential new prognostic biomarker thanks to new insight into the aggressive behavior of certain adult B-acute lymphoblastic leukemias.
